Derivative exercise or conversion — not an open-market buy.
Loading…
Traded Aug 18, 2026 · Filed Aug 20, 2026
A board member of Charles River Laboratories sold $163K of Charles River Laboratories shares. Nobody planned it ahead of time.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell
open market sale
Code S — open-market or private sale
~$163,443
Shares × reported transaction price
13 days after results of Aug 5, 2026
Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results
Closed at $279.19 on Aug 18, 2026, within 3% of its 52-week high, after a 22% rise over the previous 30 trading days
52-week range $145.57 (Sep 25, 2025) to $286.64 (Aug 17, 2026), 95% of the way up, from 251 adjusted closes. 30 trading days earlier: $228.68 on Jul 7, 2026. Describes the past only, not a forecast
None found in footnotes
Only flagged when a footnote says so; never inferred
| After | Stock | S&P 500 | Difference |
|---|---|---|---|
| 7 days | -1.3% | +0.5% | -1.7% |
| 30 days | -5.5% | +1.0% | -6.5% |
Past results only. Not a forecast.
Derivative exercise or conversion — not an open-market buy.
Derivative exercise or conversion — not an open-market buy.
Director sold ~$10.1M of Charles River Laboratories
Scheduled in advance
